The purpose of this study is to compare post-vaccination reactions between theprotein-based Novavax vaccine and the mRNA Pfizer vaccine. Specifically, the study aimsto determine the rate of participant-reported symptoms associated with each type ofvaccine.
Why are we doing this study? Many people get a flu shot each year, but not as many get
the COVID-19 booster, even though COVID-19 can be more serious. One reason might be that
some people are worried about side effects from the vaccine.
We want to learn whether a different kind of COVID-19 vaccine, called Novavax, causes
fewer side effects than the more commonly used mRNA vaccines (like Pfizer or Moderna)
when given as a seasonal booster.
What is Novavax? Novavax is a protein-based COVID-19 vaccine that has been approved by
the FDA. Earlier studies suggest that people may have fewer side effects with Novavax,
but not many studies have directly compared it to mRNA vaccines
What is the purpose of this study? We are inviting you to join this study because you are
eligible to receive a COVID-19 booster. If you choose to participate, you will receive
either the Novavax vaccine or an mRNA vaccine. After your shot, we'll ask you how you
feel. This helps us learn which vaccine may be easier on the body.
Why does this matter? By comparing experiences from different people, we hope to find
ways to make COVID-19 boosters more acceptable and accessible. This could help more
people feel confident about getting vaccinated and staying protected.
Drug: Nuvaxovid (NVX-CoV2705)
COVID-19 vaccination
Drug: Pfizer-BioNTech COVID-19 vaccine
COVID-19 vaccination
Inclusion Criteria:
Adults eligible for seasonal COVID-19 vaccine, ages 18 and older Signed informed consent
form (ICF) and agree to participate in the study Prior receipt of one or more COVID-19
vaccines
Exclusion Criteria:
- If a person is experiencing a moderate or severe illness or infection (as judged by
the study investigator) or has a fever (temperature of 38.0°C or higher) on the day
they are supposed to participate in the study, they should not join until they are
feeling better and the fever is gone.
- Anyone with a medical or mental health issue, or problems with substance use that
might make taking part in the study risky
- People who have had a severe allergic reaction to COVID-19 vaccines in the past
- Those who have been diagnosed with inflammation in or around the heart after
receiving a COVID-19 vaccine
- Individuals who have received any other vaccine within a week before joining the
study or who plan to get a vaccine on the same day as the study or within 7 days
afterward
Oregon Health and Sciences University
Portland, Oregon, United States
Investigator: Marcel E Curlin, MD
Contact: 503-494-6633
curlin@ohsu.edu
Not Provided